Related Experiment Video

Updated: Jul 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic adenoviruses for cancer gene therapy

Ta-Chiang Liu1, Stephen H Thorne, David H Kirn

  • 1Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Methods in Molecular Biology (Clifton, N.J.)
|August 6, 2008
PubMed

Insights

Replication-competent oncolytic viruses offer a promising platform for cancer gene therapy due to their self-perpetuating nature and ability to deliver therapeutic transgenes. This chapter details methods for studying oncolytic virus replication in vitro and in vivo.

Area of Science:

  • Oncolytic virotherapy
  • Cancer gene therapy
  • Molecular virology

Background:

  • Replication-competent oncolytic viruses represent a significant advancement in cancer gene therapy.
  • Their unique mechanisms and self-perpetuating nature make them ideal for therapeutic transgene insertion.
  • Achieving tumor selectivity is crucial and can be engineered through various strategies.

Purpose of the Study:

  • To describe common assays for studying oncolytic viruses.
  • To emphasize methods for determining viral replication both in vitro and in vivo.
  • To highlight the potential of oncolytic viruses in cancer treatment.

Main Methods:

  • Utilizing adenovirus as a model system.
  • Describing assays for assessing viral replication.
  • Focusing on both laboratory-based (in vitro) and whole-organism (in vivo) studies.

Main Results:

  • Oncolytic viruses can be engineered for tumor selectivity.
  • Therapeutic transgenes can be amplified with viral replication, enhancing efficacy.
  • Established assays allow for the quantification of viral replication.

Conclusions:

  • Oncolytic viruses are a versatile tool in cancer gene therapy.
  • Effective study methodologies are essential for optimizing their therapeutic application.
  • Further research into oncolytic virus assays will advance cancer treatment strategies.

More Related Videos

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction04:43

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction

Published on: October 11, 2024

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...